# A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

Source: https://onco.cc/trials/nct07230106/  
OnCo record `nct07230106` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HS-20093, Rezvilutamide, Abiraterone acetate in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer is a phase 2 interventional study registered as NCT07230106 by Jiangsu HengRui Medicine Co., Ltd., with 218 participants planned, started 2025-12-08 and due to reach its primary completion in 2028-12. Interventions recorded: HS-20093 for Injection, SHR3680 Tablet, Abiraterone Tablet, SHR2554 Tablet, Enzalutamide Tablet. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07230106
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 218

## Sources

- ClinicalTrials.gov NCT07230106: https://clinicaltrials.gov/study/NCT07230106

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [HS-20093](https://onco.cc/drugs/hs-20093/), [Rezvilutamide](https://onco.cc/drugs/rezvilutamide/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07230106.json